Expectations trend
FY2028 · fiscal year ending 2028-06-30 · fmp
Bio-Techne (TECH)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$72.66-0.10%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
2.35 → 2.36 EPS · FY ending Jun 30, 2028 · 5 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 5 to 5; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for TECH yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain quarterly dividend of $0.08 per share | It keeps paying a steady dividend of $0.08 per share. | Intact | Dividend per share falls below $0.08 | Dividend per share: $0.08 per share FY2026-Q3; GAAP. Published target: >= $0.08 per share. The target does not explicitly identify fiscal versus calendar quarters. May 6, 20260.08 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-06-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
TECH is a healthcare business with strong recent financial performance and a sector tailwind, but it is not a steady-growth story yet. Its multi-year view is intact, with medium confidence, while risk has recently risen from moderate to elevated.
The valuation is expensive versus peers, and the expectations gap suggests meaningful growth expectations are already reflected. The evidence labels that pricing as unjustified, though the fragility rating is low because the concerns are not stacked across valuation, weak results, and turbulence.
Near term, results have been strong relative to the industry and the latest reported quarter included an earnings beat. Over the multi-year view, revenue delivery remains mixed: fiscal 2026 revenue was slightly below fiscal 2025, while recent organic growth was flat to slightly positive; adjusted margins stayed near 32% with only slight operating-income growth.
A guidance cut on the next call would be a meaningful negative, especially if estimates are then revised lower. A further weakening in jobs data could add pressure to cyclical healthcare names, while continued earnings strength and higher guidance from sector bellwethers could support sector momentum. The evidence for the recently announced acquisition is thin, so its effect on the thesis is not yet clear.
For the next 1 to 3 years, TECH combines strong recent performance and sector support with mixed growth execution, elevated risk, and expensive valuation. The long-term thesis depends on management turning its growth priorities into steadier results without a guidance setback. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Bio-Techne improves profit margins from 12.2% to 24.2% in one year. |
| Intact |
| Operating margin falls below 15% in 2026-Q3 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 4 of 8 supplied quarters. Management reported: “ ● Ongoing productivity and cost containment initiatives led to 29.9% adjusted operating margin, an increase of 90 basis points compared to the prior year period.” “Our continued focus on profitability resulted in a 34.9% adjusted operating margin, an increase of 190 basis points compared to the prior year period.”” Delivery assessment Nov 4, 2026 |
Maintain revenue near $311 million in Q3 2026 | Revenue is stable near $311 million despite market challenges. | Intact | Revenue falls below $295 million in 2026-Q3 | Revenue: $321.192M FY2026-Q4; GAAP. Published target: >= $311 million. The stored target says 2026-Q3; this source reports FY2026-Q4. Fiscal/calendar alignment needs review. Aug 24, 2026321,192,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 8 supplied quarters. Management reported: “ ● Strong performance in our proteomic analytic and cell therapy growth pillars drove 4% organic growth (6% reported) in the Protein Sciences segment for the quarter, and 5% organic and reported growth for the full year.” “Our portfolio is organized to support durable, high-value applications across the scientific journey, from biological discovery and translational insight to therapeutic development, manufacturing, and precision diagnostics.” Delivery assessment Nov 4, 2026 |
Smooth integration of Merck KGaA acquisition | The acquisition by Merck KGaA boosts growth and market position. | Intact | Material integration problems or loss of key customers reported | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$2.32 → $2.36 · observed estimates
$1.38B → $1.40B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $2.32 | $1,382,965,993 | 3 / 9 |
| 2026-07-25 | $2.32 | $1,382,965,993 | 3 / 9 |
| 2026-07-26 | $2.32 | $1,382,965,993 | 3 / 9 |
| 2026-07-27 | $2.32 | $1,382,965,993 | 3 / 9 |
| 2026-07-28 | $2.32 | $1,382,965,993 | 3 / 9 |
| 2026-07-29 | $2.32 | $1,382,965,993 | 3 / 9 |
| 2026-07-30 | $2.32 | $1,382,965,993 | 3 / 10 |
| 2026-07-31 | $2.32 | $1,382,965,993 | 3 / 10 |
| 2026-08-01 | $2.32 | $1,382,965,993 | 3 / 10 |
| 2026-08-02 | $2.32 | $1,386,148,378 | 3 / 9 |
| 2026-08-03 | $2.32 | $1,386,148,378 | 3 / 9 |
| 2026-08-04 | $2.32 | $1,386,148,378 | 3 / 10 |
| 2026-08-05 | $2.32 | $1,386,148,378 | 3 / 10 |
| 2026-08-06 | $2.32 | $1,386,148,378 | 3 / 10 |
| 2026-08-08 | $2.32 | $1,386,148,378 | 3 / 10 |
| 2026-08-09 | $2.32 | $1,386,148,378 | 3 / 10 |
| 2026-08-10 | $2.32 | $1,386,148,378 | 3 / 10 |
| 2026-08-12 | $2.32 | $1,386,148,378 | 3 / 10 |
| 2026-08-13 | $2.32 | $1,386,148,378 | 3 / 10 |
| 2026-08-14 | $2.32 | $1,386,148,378 | 3 / 10 |
| 2026-08-15 | $2.32 | $1,386,148,378 | 3 / 10 |
| 2026-08-16 | $2.32 | $1,386,148,378 | 3 / 10 |
| 2026-08-17 | $2.32 | $1,386,148,378 | 3 / 10 |
| 2026-08-18 | $2.32 | $1,386,148,378 | 3 / 10 |
| 2026-08-19 | $2.32 | $1,386,148,378 | 3 / 10 |
| 2026-08-20 | $2.34 | $1,380,131,740 | 3 / 6 |
| 2026-08-21 | $2.34 | $1,380,131,740 | 3 / 6 |
| 2026-08-22 | $2.34 | $1,380,131,740 | 3 / 6 |
| 2026-08-23 | $2.34 | $1,380,131,740 | 3 / 6 |
| 2026-08-24 | $2.34 | $1,380,131,740 | 3 / 6 |
| 2026-08-25 | $2.34 | $1,380,131,740 | 3 / 6 |
| 2026-08-26 | $2.34 | $1,380,131,740 | 3 / 6 |
| 2026-08-27 | $2.34 | $1,380,131,740 | 3 / 6 |
| 2026-08-28 | $2.34 | $1,380,131,740 | 3 / 6 |
| 2026-08-29 | $2.34 | $1,390,868,100 | 3 / 6 |
| 2026-08-30 | $2.34 | $1,390,868,100 | 3 / 6 |
| 2026-08-31 | $2.34 | $1,390,868,100 | 3 / 6 |
| 2026-09-01 | $2.34 | $1,390,868,100 | 3 / 6 |
| 2026-09-02 | $2.34 | $1,390,868,100 | 3 / 6 |
| 2026-09-03 | $2.34 | $1,390,868,100 | 3 / 6 |
| 2026-09-04 | $2.34 | $1,390,868,100 | 3 / 6 |
| 2026-09-05 | $2.34 | $1,390,868,100 | 3 / 6 |
| 2026-09-06 | $2.34 | $1,390,868,100 | 3 / 6 |
| 2026-09-07 | $2.34 | $1,390,868,100 | 3 / 6 |
| 2026-09-08 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-09 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-10 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-11 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-12 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-13 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-14 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-15 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-16 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-17 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-18 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-19 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-20 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-21 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-22 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-23 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-24 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-25 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-26 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-27 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-28 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-29 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-09-30 | $2.34 | $1,390,868,100 | 5 / 7 |
| 2026-10-01 | $2.33 | $1,392,935,125 | 5 / 7 |
| 2026-10-02 | $2.33 | $1,392,935,125 | 5 / 7 |
| 2026-10-03 | $2.36 | $1,392,935,125 | 5 / 7 |
| 2026-10-04 | $2.36 | $1,392,935,125 | 5 / 7 |
| 2026-10-05 | $2.35 | $1,390,426,714 | 5 / 7 |
| 2026-10-06 | $2.35 | $1,390,426,714 | 5 / 7 |
| 2026-10-07 | $2.35 | $1,390,426,714 | 5 / 7 |
| 2026-10-08 | $2.38 | $1,397,414,500 | 5 / 7 |
| 2026-10-09 | $2.38 | $1,397,414,500 | 5 / 7 |
| 2026-10-10 | $2.38 | $1,397,414,500 | 5 / 7 |
| 2026-10-11 | $2.38 | $1,397,414,500 | 5 / 7 |
| 2026-10-12 | $2.38 | $1,397,414,500 | 5 / 7 |
| 2026-10-13 | $2.38 | $1,397,414,500 | 5 / 7 |
| 2026-10-14 | $2.38 | $1,397,414,500 | 5 / 7 |
| 2026-10-15 | $2.38 | $1,397,414,500 | 5 / 7 |
| 2026-10-16 | $2.38 | $1,397,414,500 | 5 / 7 |
| 2026-10-17 | $2.38 | $1,397,414,500 | 5 / 7 |
| 2026-10-18 | $2.38 | $1,397,414,500 | 5 / 7 |
| 2026-10-19 | $2.38 | $1,397,414,500 | 5 / 7 |
| 2026-10-20 | $2.38 | $1,397,414,500 | 5 / 7 |
| 2026-10-21 | $2.38 | $1,397,414,500 | 4 / 7 |
| 2026-10-22 | $2.38 | $1,397,414,500 | 4 / 7 |
| 2026-10-23 | $2.38 | $1,397,414,500 | 4 / 7 |
| 2026-10-24 | $2.38 | $1,398,414,167 | 4 / 7 |
| 2026-10-25 | $2.38 | $1,398,414,167 | 4 / 7 |
| 2026-10-26 | $2.38 | $1,398,414,167 | 4 / 7 |
| 2026-10-27 | $2.38 | $1,398,414,167 | 4 / 7 |
| 2026-10-28 | $2.38 | $1,398,414,167 | 5 / 7 |
| 2026-10-29 | $2.36 | $1,398,414,167 | 5 / 7 |
| 2026-10-30 | $2.36 | $1,398,414,167 | 5 / 7 |
| 2026-10-31 | $2.36 | $1,398,414,167 | 5 / 7 |
| 2026-11-01 | $2.36 | $1,398,414,167 | 5 / 7 |
| 2026-11-02 | $2.36 | $1,398,414,167 | 5 / 7 |
| 2026-11-03 | $2.36 | $1,398,414,167 | 5 / 7 |
| 2026-11-04 | $2.36 | $1,398,414,167 | 5 / 7 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 12 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.